Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Dose Regimens in Relapsed/Refractory CLL
NCT00963105Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2009
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by Celgene Corporation. Started Oct 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00963105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00963105.